tiprankstipranks
Protagonist Therapeutics price target raised to $38 from $33 at H.C. Wainwright
The Fly

Protagonist Therapeutics price target raised to $38 from $33 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Protagonist Therapeutics to $38 from $33 and keeps a Buy rating on the shares. The company announced positive topline results from the randomized withdrawal portion of the REVIVE study for rusfertide in polycythemia vera that provide validation to the drug’s favorable safety profile, the analyst tells investors in a research note. To reflect increased confidence on rusfertide, the firm raised its probability of success to 55% from 50%.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on PTGX:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles